Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (3)
Type
Type
Guidance (766)
Guidance programme
(
1 selected
)
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (223)
COVID-19 rapid guidelines (3)
Diagnostics guidance (47)
Health technology evaluations (18)
Highly specialised technologies guidance (28)
Interventional procedures guidance (601)
Medical technologies guidance (67)
Medicines practice guidelines (5)
NICE guidelines (339)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (766)
Apply filters
Showing 101 to 150 of 766
Sort by
Date
Title
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
TA897
6 June 2023
6 June 2023
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)
TA899
6 June 2023
6 June 2023
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
TA891
31 May 2023
31 May 2023
Mosunetuzumab for treating relapsed or refractory follicular lymphoma
TA892
31 May 2023
31 May 2023
Risankizumab for previously treated moderately to severely active Crohn's disease
TA888
17 May 2023
17 May 2023
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)
TA889
17 May 2023
17 May 2023
Difelikefalin for treating pruritus in people having haemodialysis
TA890
17 May 2023
17 May 2023
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
TA886
10 May 2023
10 May 2023
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
TA887
10 May 2023
10 May 2023
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments
TA881
3 May 2023
3 May 2023
Voclosporin with mycophenolate mofetil for treating lupus nephritis
TA882
3 May 2023
3 May 2023
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
TA883
3 May 2023
3 May 2023
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)
TA884
3 May 2023
3 May 2023
Tezepelumab for treating severe asthma
TA880
20 April 2023
20 April 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)
TA879
6 April 2023
6 April 2023
Finerenone for treating chronic kidney disease in type 2 diabetes
TA877
23 March 2023
23 March 2023
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
TA876
22 March 2023
22 March 2023
Eptinezumab for preventing migraine
TA871
1 March 2023
1 March 2023
Cannabidiol for treating seizures caused by tuberous sclerosis complex
TA873
1 March 2023
1 March 2023
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
TA874
1 March 2023
1 March 2023
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
TA872
28 February 2023
28 February 2023
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
TA870
22 February 2023
22 February 2023
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)
TA867
16 February 2023
16 February 2023
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)
TA869
16 February 2023
16 February 2023
Vutrisiran for treating hereditary transthyretin-related amyloidosis
TA868
15 February 2023
15 February 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
TA865
8 February 2023
8 February 2023
Regorafenib for previously treated metastatic colorectal cancer
TA866
8 February 2023
8 February 2023
Upadacitinib for treating active non-radiographic axial spondyloarthritis
TA861
1 February 2023
1 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
TA862
1 February 2023
1 February 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over
TA863
1 February 2023
1 February 2023
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
TA864
1 February 2023
1 February 2023
Maribavir for treating refractory cytomegalovirus infection after transplant
TA860
18 January 2023
18 January 2023
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)
TA859
16 January 2023
16 January 2023
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
TA857
11 January 2023
11 January 2023
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
TA858
11 January 2023
11 January 2023
Upadacitinib for treating moderately to severely active ulcerative colitis
TA856
4 January 2023
4 January 2023
Avatrombopag for treating primary chronic immune thrombocytopenia
TA853
15 December 2022
15 December 2022
Cabozantinib for previously treated advanced hepatocellular carcinoma
TA849
14 December 2022
14 December 2022
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
TA850
14 December 2022
14 December 2022
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer
TA851
14 December 2022
14 December 2022
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments
TA852
14 December 2022
14 December 2022
Esketamine nasal spray for treatment-resistant depression
TA854
14 December 2022
14 December 2022
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)
TA848
1 December 2022
1 December 2022
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)
TA845
29 November 2022
29 November 2022
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)
TA846
29 November 2022
29 November 2022
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)
TA847
29 November 2022
29 November 2022
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)
TA844
24 November 2022
24 November 2022
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)
TA843
24 November 2022
24 November 2022
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
TA841
22 November 2022
22 November 2022
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)
TA842
22 November 2022
22 November 2022
Previous page
1
2
Current page
3
4
5
…
16
Page
3
of
16
Next page
Results per page
10
25
50
All
Back to top